Journal of Clinical Oncology
Articles in this Issue
Lung cancer combined with interstitial lung disease: Controversial role of preexisting hypertension and emphysema observed in a fully followed 20-year patient cohort.
10556 Background: The coexistence of interstitial lung diseases (ILD) and lung cancer (LC) presents a clinical challenge. ILD, including idiopathic pulmon...
Gold complex 2G and its role in immunogenic cell death and antitumor immunity in malignant pleural mesothelioma.
e20095 Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated with asbestos exposure, characterized by an immunologically...
GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients.
TPS8114 Background: Lung cancer is the global leading cause of cancer deaths. Despite treatment advances, NSCLC outcomes remain poor. The molecular landsc...
Characterization and impact of B7-H3 ( <i>CD276</i> ) expression across disease states and racial groups in prostate cancer.
5073 Background: B7-H3 ( CD276 ) is an immunomodulatory protein overexpressed in prostate cancer (PC), representing a promising th...
Racial differences in palliative care use and clinical outcomes among hospitalized lung cancer patients: Insights from the 2021 National Inpatient Sample.
e24055 Background: Lung cancer remains the leading cause of cancer-related mortality in the U.S., with limited survival despite advances in treatment. Pal...
Early detection of lung cancer in smokers using miRNA profiles and a hybrid deep learning framework.
e13682 Background: Lung cancer remains the primary cause of cancer-related mortality globally, with early diagnosis being crucial for improving patient su...
Epidemiology and outcomes of aspiration pneumonia in White American patients hospitalized with nasopharyngeal cancer: A nationwide analysis.
e18104 Background: Nasopharyngeal cancer (NPC) is commonly linked to dysphagia, which can result from tumor invasion or treatment-related side effects, su...
Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.
11083 Background: To evaluate the implementation of a pilot patient-ambassador program to provide peer-to-peer clinical trial education aimed at increasin...
Implementation of an academic precision oncology service in a community setting.
1531 Background: Implementation of precision oncology (PO) in community practice remains challenging due to insufficient resources to order and interpret...
Investigating the role of immunosurveillance by macrophage in supporting therapeutic strategies using CD47 blockade in MDS.
e18582 Background: Myelodysplastic syndrome (MDS) is characterised by disturbances in the maturation and differentiation of haematopoietic stem cells. Whi...
IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: Updated results from a phase I trial.
5565 Background: IBI354 is an antibody-drug conjugate consisting of trastuzumab (anti-HER2 antibody) conjugated to a topoisomerase I inhibitor. It has sho...
mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody vs. mFOLFOX6 in locally advanced pMMR/MSS CRC: A multicenter, randomized controlled phase III study (BASKETIII).
TPS3646 Background: Immunotherapy has shown promising therapeutic effects in mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) col...
Survival trends in older adults with anaplastic thyroid cancer (ATC): A SEER database study.
e18164 Background: ATC is a rare but aggressive type of thyroid cancer, accounting for 1-2% of all thyroid cancers. It is known to be a disease of older a...
OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic <i>RAS/BRAF</i> wild-type colorectal cancer.
TPS3638 Background: Among patients with metastatic colorectal cancer (mCRC), approximately 50% are wild-type for KRAS ,...
Factors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis.
11168 Background: The frontline treatments for metastatic colon cancer (mCC) include intensive therapies (e.g., doublet or triplet chemotherapy backbones...
Multi-omic analysis and overall survival update of phase II TRIDENT study: Durvalumab plus olaparib in extensive-stage small-cell lung cancer (ES-SCLC).
8101 Background: Chemotherapy plus anti-PD1/PD-L1 therapy has revolutionized the standard first-line treatment for patients with ES-SCLC. Durvalumab plus...
Leveraging advanced practice providers in a clinical research program to provide trial prescreening and counseling increases clinic volume and trial accruals.
e13529 Background: Stanford Health Care’s Early Drug Development program (EDD) enables Principal Investigators (PI) throughout the Cancer Center to open e...
Patterns of early and late recurrence across breast cancer subtypes in the CCTGMA.32 trial.
534 Background: An ongoing constant risk of recurrence out to 20 years is well established in hormone receptor positive breast cancer (BC) less so in othe...
Pharmacist-led medication reconciliation televisit (MRT) for phase 1 oncology clinical trials: A telemedicine model.
1500 Background: Accurate medication reconciliation is critical in oncology trials to mitigate drug-drug interactions (DDIs), address eligibility and enha...
Demographic and genomic landscape of early mortality in patients with stage IV non–small-cell lung cancer.
11054 Background: Early mortality presents an ongoing challenge to oncologists all over the world. Specifically, one-third of patients that present with l...
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.
e16147 Background: The perioperative treatment of gastric and gastroesophageal junction (GC/GEJ) adenocarcinoma is being investigated through a combinatio...
Clinical implications and prevalence of benign ethnic neutropenia (BEN) in breast cancer patients of Middle Eastern ethnicity.
1601 Background: Benign ethnic neutropenia (BEN) commonly affects patients of African and Middle-Eastern descent and is not a true neutropenic state. Pati...
Modification of the novel RANO clinical risk score for low- and middle-income countries without access to MGMT methylation testing.
2052 Background: The RANO Resect Group developed a new risk score using simple variables, including age, Karnofsky performance scale (KPS), RANO resection...
Patterns of cardiac monitoring and outcomes in patients with HER2-positive breast cancer treated with a trastuzumab-based regimen in a safety-net system.
e24027 Background: Targeting HER-2 receptor with monoclonal antibodies is the mainstay of treatment in HER2-positive breast cancer and can result in cardi...
An open-label phase 1 dose-escalation and dose-expansion trial to evaluate the safety, tolerability, and efficacy of TQ-B3234 in adults with neurofibromatosis type 1 (NF1).
3108 Background: NF1 is an autosomal-dominant genetic disease that can manifest as neurofibromas, including cutaneous neurofibromas (cNFs) affecting almos...